Zunyi

This trial studies patients with limited stage small cell lung cancer who have not shown disease progression after concurrent chemoradiation therapy. It is a randomized, double-blind, phase III clinical study designed to compare the effectiveness and safety of the drug AK112 against a placebo as a consolidation treatment. The goal is to evaluate the potential benefits of AK112 in improving outcomes for these patients. Participants receive either AK112 at a dose of 20 mg/kg or a placebo, both administered intravenously every three weeks (Q3W). The treatment is given as consolidation therapy following initial chemoradiation, aiming to maintain disease control. The study involves two groups: one receiving AK112 and the other receiving placebo, with both treatments delivered under double-blind conditions. Throughout the trial, researchers monitor participants for up to approximately six years, focusing on progression-free survival and overall survival as primary outcomes. Patients undergo regular assessments to track disease status and safety, including blinded independent center reviews. The long-term follow-up ensures comprehensive evaluation of treatment effects and participant safety over time.

This observational study focuses on investigating the proportion of latent tuberculosis infection among students who have been in close contact with active tuberculosis patients in school settings. It aims to identify how common Mycobacterium tuberculosis infection is in these contacts, explore risk factors related to TB infection, and assess the health economic aspects of screening strategies for tuberculosis. Participants will be tested using the QuantiFERON-TB Gold (QFT) test to detect prior infection with Mycobacterium tuberculosis. Those who test positive will undergo additional evaluations including sputum Xpert MTB/RIF testing, physical examinations, chest CT scans, and sputum cultures as needed to distinguish latent TB infection from active tuberculosis. Chest X-ray scans are performed if the participant is older than 15 years and has a positive QFT result. During the study, participants will be monitored through these diagnostic tests and examinations to determine the presence of TB infection. Researchers will measure the prevalence of tuberculosis infection at baseline among school contacts. The study includes students aged 13 years and older who have had close contact with active TB cases in school environments such as classrooms or dormitories. Participation involves signing informed consent, with guardian involvement for minors.